TY  - JOUR
AU  - Schweitzer, Finja
AU  - Laurent, Sarah
AU  - Fink, Gereon Rudolf
AU  - Barnett, Michael H.
AU  - Reddel, Stephen
AU  - Hartung, Hans-Peter
AU  - Warnke, Clemens
TI  - Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis
JO  - Current opinion in neurology
VL  - 32
IS  - 3
SN  - 1350-7540
CY  - [S.l.]
PB  - Ovid
M1  - FZJ-2019-02818
SP  - 305 - 312
PY  - 2019
AB  - A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit–risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events.
LB  - PUB:(DE-HGF)16
C6  - pmid:30985373
UR  - <Go to ISI:>//WOS:000480723400001
DO  - DOI:10.1097/WCO.0000000000000701
UR  - https://juser.fz-juelich.de/record/862515
ER  -